Swan Capital LLC Summit Therapeutics Inc. Transaction History
Swan Capital LLC
- $205 Billion
- Q4 2024
A detailed history of Swan Capital LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Swan Capital LLC holds 15 shares of SMMT stock, worth $288. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15Holding current value
$288% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$470 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$225 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$152 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$126 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$108 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.87B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...